A technology forged in the crucible of a global pandemic has now turned its attention to one of humanity's oldest seasonal adversaries. For the first time, Americans can receive an mRNA-based influenza vaccine — the same platform that redefined COVID-19 protection — as the 2026-27 flu season begins. Health authorities are guiding the public toward pharmacies, clinics, and community health programs where the shot is already available. This moment marks not merely a new product, but a potential turning point in how societies prepare for the recurring rhythms of respiratory illness.